These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 29028787)
1. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787 [TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
3. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation. Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577 [TBL] [Abstract][Full Text] [Related]
4. Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma. Huang CY; Wang H; Liao W; Han F; Li YQ; Chen SW; Lao XM J Immunother; 2017 Jun; 40(5):175-186. PubMed ID: 28394813 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206 [TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. Umemoto Y; Okano S; Matsumoto Y; Nakagawara H; Matono R; Yoshiya S; Yamashita Y; Yoshizumi T; Ikegami T; Soejima Y; Harada M; Aishima S; Oda Y; Shirabe K; Maehara Y J Gastroenterol; 2015 Jan; 50(1):65-75. PubMed ID: 24509608 [TBL] [Abstract][Full Text] [Related]
7. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366 [TBL] [Abstract][Full Text] [Related]
8. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091 [TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541 [TBL] [Abstract][Full Text] [Related]
11. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Wu K; Kryczek I; Chen L; Zou W; Welling TH Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049 [TBL] [Abstract][Full Text] [Related]
12. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor PD-L1 expression combined with CD8 Wang Q; Lou W; Di W; Wu X Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888 [TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272 [TBL] [Abstract][Full Text] [Related]
16. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947 [TBL] [Abstract][Full Text] [Related]
19. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
20. PD-1 Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]